Gastric-type adenocarcinoma of the uterine cervix (GAS) is a rare variant of mucinous endocervical adenocarcinoma not etiologically associated with human papillomavirus (HPV) infection, with minimal deviation adenocarcinoma (MDA) at the well-differentiated end of the morphologic spectrum. These tumors are reported to have worse prognosis than usual HPV associated endocervical adenocarcinoma (UEA). A retrospective review of GAS was performed from the pathology databases of 3 institutions spanning 20 years. Stage, metastatic patterns, and overall survival were documented. Forty GAS cases were identified, with clinical follow-up data available for 38. The tumors were subclassified as MDA (n = 13) and non-MDA GAS (n = 27). Two patients were syndromic (1 Li-Fraumeni, 1 Peutz-Jeghers). At presentation, 59% were advanced stage (FIGO II to IV), 50% had lymph node metastases, 35% had ovarian involvement, 20% had abdominal disease, 39% had at least 1 site of metastasis at the time of initial surgery, and 12% of patients experienced distant recurrence. The metastatic sites included lymph nodes, adnexa, omentum, bowel, peritoneum, diaphragm, abdominal wall, bladder, vagina, appendix, and brain. Follow-up ranged from 1.4 to 136.0 months (mean, 33.9 mo); 20/38 (52.6%) had no evidence of disease, 3/38 (7.9%) were alive with disease, and 15/38 (39.5%) died of disease. Disease-specific survival at 5 years was 42% for GAS versus 91% for UEA. There were no survival differences between MDA and non-MDA GAS. GAS represents a distinct, biologically aggressive type of endocervical adenocarcinoma. The majority of patients present at advanced stage and pelvic, abdominal, and distant metastases are not uncommon.
proximately 20% to 25% of cervical cancers, with increasing incidence in recent years. [1] [2] [3] [4] [5] The 2014 World Health Organization Classification of Tumours of Female Reproductive Organs includes gastric-type adenocarcinomas (GAS) as a variant of mucinous ECA (Table 1) . 6 By far the most common type of adenocarcinoma is the usual type (UEA); this is associated with high-risk human papillomavirus (HPV) infection, most commonly HPV types 16 and 18. However, unlike cervical squamous cell carcinoma where nearly all cases are etiologically associated with HPV infection, approximately 10% of ECAs in western countries are unrelated to HPV. 7, 8 Therefore, ECA can be subclassified into HPV-associated and HPV-unassociated groups ( Table 2 ). The HPV-associated ECAs can have a variety of morphologic appearances, including mucinous features, with or without intestinal differentiation, and they may resemble endometrioid and serous carcinomas. The HPV-unassociated group includes clear cell, mesonephric, and gastric type, including minimal deviation adenocarcinomas (MDA), also known as adenoma malignum. [9] [10] [11] MDA are characterized by deceptively low histologic grade, often with neoplastic glands almost indistinguishable from benign endocervical glands. [12] [13] [14] [15] [16] They exhibit abundant apical mucin, basally oriented nuclei, and, characteristically, little or only very subtle cervical stromal reaction to invasion, making it difficult to diagnose in cervicovaginal cytology preparations, biopsies, conization specimens, and even hysterectomies. Sometimes deep cervical stromal involvement may be the only overt feature supporting a malignant diagnosis. Clinical outcomes in MDA have been a matter of considerable debate with several studies indicating its aggressive biologic nature, especially compared with UEA, 12, 14, 16 whereas other reports have stated that the difference may not be independent of stage. 15 In addition, MDA has been linked to Peutz-Jeghers syndrome in up to 10% of cases. [17] [18] [19] Several recent studies have described a new category of mucinous ECA, GAS, which has a distinctive histologic appearance and immunohistochemical (IHC) profile as well as poor clinical outcomes. 9, 16, 19 Histologic criteria for GAS were first defined by Kojima et al 16 to include FIGURE 1 . A, GAS with voluminous clear cytoplasm and basally located nuclei with moderate cytologic atypia, adjacent small invasive tumor clusters (H&E). B, LEGH with central dilated gland and smaller glands proliferating along the periphery, similar to pancreatic ducts (H&E). C, Goblet cell and neurosecretory-like granules in glands of GAS (H&E). H&E indicates hematoxylin and eosin.
cells showing clear and/or pale eosinophilic and voluminous cytoplasm with distinct cell borders comprising the majority of the tumor. In some cases, benign endocervical glands showing "gastric metaplasia" resembling normal pyloric glands of the antral stomach are found adjacent to invasive adenocarcinoma, and these tumors frequently contain areas that are indistinguishable from MDA. There is histochemical, IHC, and etiologic overlap as well: both lesions feature acidic mucin and an IHC profile similar to normal gastric mucus cells, with expression of HIK1083, lysozyme, and pepsinogen II. 13, 16 They are negative for HPV DNA (by polymerase chain reaction) and p16 (by IHC), with only rare exceptions. The term "lobular endocervical glandular hyperplasia" (LEGH) was first coined by Nucci et al 20 to describe a benign pseudoneoplastic endocervical process resembling MDA. Almost simultaneously, Mikami et al 21 described a series of similar lesions using the terminology "pyloric gland metaplasia." Subsequently, LEGH was shown to have features of gastric metaplasia and, similar to GAS, had a gastric-type IHC profile, [22] [23] [24] [25] [26] prompting some authors to consider LEGH to be a putative precursor lesion to MDA and GAS. 22, 25, 27, 28 Kojima's landmark study looked at only 16 cases of GAS (including MDA). 16 Here, we characterize the clinical outcomes of patients with GAS (including MDA), focusing not only on overall survival but also on other clinical variables such as sites of metastasis and recurrence.
MATERIALS AND METHODS
Patients diagnosed with GAS at Memorial Sloan Kettering Cancer Center (MSK) from January 1, 1997 to January 1, 2012 were identified. Additional cases (spanning the period between January 1, 1998 and January 1, 2009) were also included from 2 collaborating institutions (Jikei University, Tokyo, Japan; Yale University School of Medicine, New Haven, CT).
Hematoxylin and eosin-stained histologic sections were reviewed by 2 pathologists (Y.S.K. and K.J.P.) and the diagnoses were established using the criteria described by Kojima et al. 16 Specifically, tumors showed voluminous clear and/or pale eosinophilic cytoplasm with distinct cell borders in a significant portion of the tumor. None of the tumors showed the typical features of UEA (columnar nuclei with abundant apoptotic bodies and luminal mitotic figures). The results of p16 IHC performed for diagnostic purposes in any case were also recorded. All relevant pathologic and clinical data were collected and analyzed. Recurrent histologic findings, including association with LEGH, were recorded and analyzed. The findings were compared to a cohort of 158 usual HPV-associated ECA identified at MSK between January 1, 2002 and January 1, 2012.
Although we consider MDA to be a part of the morphologic spectrum of GAS, we collected separate data for these tumors for the purposes of this study to determine whether there were associations between histologic differentiation and clinical biology. Tumors were classified as MDA when the bulk of tumor in the cervix (Z90%) was cytologically low grade (minimal nuclear atypia, abundant apical mucin) with well-formed glands sometimes showing the classically described "claw-like" growth pattern and some stromal desmoplasia. Any cases where the presence of an invasive tumor was equivocal by histologic standards were excluded from our study. Tumors were classified as non-MDA when at least 10% of the tumor in the cervix revealed high-grade nuclei, prominent nucleoli, significant architectural complexity (more complex than simple glandular, cystic, or clawshaped), single cells or clusters, or obvious extensive destructive stromal invasion. Statistical significance of the differences in proportions of cases within each histologic group having various pathologic or clinical features were made using the Fisher exact test. 29 The survival time of each patient was calculated from the date of diagnosis to date of death with right-censoring at the date of last follow-up for the patients who were still alive. The cumulative survival probabilities for each group of patients were estimated by p < 0.0001 FIGURE 2. Disease stage distribution at presentation (GAS vs. UEA) (stage I vs. II to IV). 30 The log-rank test was used to compare 2 survival curves. 31, 32 The SEs associated with the survival probabilities at a given time point were calculated from the life table by a modification of the method of Greenwood. 33, 34 
RESULTS
Forty cases were identified (MSK-29 cases, Chiba University-9 cases, and Yale University-2 cases) for which treatment information was available. Follow-up information was collected for 38 cases, as 2 patients were lost to follow up. Stage at presentation was recorded in all but one patient. All cases were diagnosed and evaluated based on sampling of the cervix (biopsy, curettage, loop electrocautery excision procedure, hysterectomy, trachelectomy, exenteration) except for 1 case where the only material available was from a peritoneal biopsy. GAS cases were further subclassified as MDA (n = 13) or non-MDA (n = 27).
Histologically, the tumors showed the features described by Kojima et al (Fig. 1A) . Additional notable features included presence of LEGH in 20% of the tumors (50% of MDA and 3.8% of non-MDA GAS) ( Fig. 1B) ; cellular dyshesion, single cell infiltration, and signet ring differentiation, especially in the non-MDA tumors and particularly prominent at the advancing edge of the cervical stromal invasion; and focal intestinal differentiation in the form of goblet (26%) or Paneth-like neuroendocrine cells (11%) (Fig. 1C ). LEGH was usually superficially located in the cervix, often admixed with adjacent invasive carcinoma but not always.
The mean age at the time of GAS diagnosis was 49.8 years (range, 30.3 to 66.8 y), and the mean follow-up period was 33.9 months (range, 1.4 to 136.0 mo). Twenty out of 38 (52.6%) patients showed no evidence of disease (NED), 3/38 (7.9%) were alive with disease (AWD), and 15/38 (39.5%) had died of disease (DOD). Separating non-MDA from MDA GAS revealed similar results between the 2 groups: mean age 49 versus 49.8; NED 13/26 (50%) versus 6/12 (50%); AWD 3/26 (12%) versus 0/12 (0%); and DOD 10/26 (38%) versus 6/12 (50%), respectively (Table 3 ).
In comparison, treatment and clinical follow-up information was available in 139 UEA cases. The mean age at time of diagnosis for UEA was 40.5 years (range, 18.2 to 82.5 y). The mean follow-up period was 50.6 months (range, 1.2 to 196.1 mo). One hundred twenty-six out of 139 (91%) patients were NED, 1/139 (1%) AWD, and 12/139 (8%) DOD (Table 3 ). Prior medical histories are summarized in Table 4 . One patient had a history of Peutz-Jeghers syndrome and another had a history of Li-Fraumeni syndrome. Two patients had histories of breast cancer, 1 patient had history of colon cancer, 1 had Wilms tumor, pheochromocytoma, and renal cell carcinoma, and 1 patient developed a subsequent mucinous bronchioloalveolar carcinoma of the lung. The Li-Fraumeni patient also had a history of breast carcinoma. The other 33 patients had no significant past medical histories. Information regarding stage distribution at the time of initial surgery/biopsy is summarized in Table 5 and Figure 2 . The majority of patients with GAS/MDA presented at advanced stage (59% stages II to IV), with only 41% presenting at stage I. Comparing non-MDA versus MDA tumors showed no statistical difference in stage at presentation (31% vs. 62% stage I, 69% vs. 38% stages II to IV, respectively, P = 0.091). In comparison, the UEA patients mostly presented at stage I (89%), with only 11% presenting at high stage (stage information available in 139 UEA patients). This difference was statistically significant from GAS/MDA (P < 0.0001). Additional routinely assessed pathologic variables included lymphovascular invasion, regional and remote lymph node involvement, ovarian and fallopian tube metastases, spread to pelvic and abdominal sites, and distant extraperitoneal spread. Notably, nearly 35% had ovarian involvement, 20% had abdominal disease, and 12% experienced extraperitoneal recurrences (see Table 6 for details). GAS tumors had higher incidences of these high-risk features as compared with UEA and there was no difference between MDA and non-MDA tumors.
GAS had significantly worse disease-specific survival than UEA (Figs. 3A, B) . Five-and 10-year survival data were calculated for all stages and for stage I only for both GAS and UEA ( Table 7) . As expected, the 5-year disease-specific survival for stage I UEA was excellent at 96%, compared with 62% for stage I GAS. When MDA cases were extracted from the group of GAS, there was no statistically significant difference in survival or recurrence rates based on histologic differentiation (Table 8 and Fig. 4 ). As mentioned previously, 2 patients had known familial syndromes. One patient had Peutz-Jeghers syndrome with the diagnosis of ECA (MDA including LEGH) being the sentinel event at age 39. She presented with stage IV disease (pT3b pN0 pM1) with peritoneal and omental involvement and underwent initial surgical management with supracervical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and peritoneal debulking, followed by chemotherapy and radiation and subsequent completion radical trachelectomy.
She currently has NED and no evidence of any other syndrome-associated neoplasia.
The second patient was diagnosed with Li-Fraumeni syndrome at the age of 30. She had a history of bilateral breast cancer at the age of 22, for which she was treated with bilateral mastectomy, chemotherapy, and tamoxifen. She presented with stage IIA2 GAS (pT2a2 Nx Mx) at age 30. She was initially managed with radiation and chemotherapy but within 6 months developed another malignancy, a diffuse astrocytoma (World Health Organization grade II) that was managed with local radiation. The patient developed metastatic GAS to retroperitoneal lymph nodes 2 years later, and metastatic GAS to bone and cerebellum 2 years after that (Fig. 5 ).
Twelve GAS patients developed recurrences compared with 6 UEA patients; this was statistically significant. The number of cases was small so there was no difference between GAS and UEA regarding sites of recurrence. Table 9 lists the sites of recurrence for each patient and whether they had MDA or non-MDA GAS histologic type.
DISCUSSION
Mucinous adenocarcinomas of the endocervix demonstrate significant clinical, etiologic, and morphologic diversity and many are unassociated with HPV infection. 7, 8 The 2014 World Health Organization classification of mucinous ECAs lists the following subtypes: gastric, intestinal, and signet ring-cell type, with minimal deviation/adenoma malignum a synonym for GAS when extremely well differentiated. 6 Our work and that of other investigators support the conclusion that GAS/MDA constitutes a unique tumor type with distinct etiologic, morphologic, IHC, and clinical features that set it apart from other mucinous ECAs 9, 11, 16, 35 (Table 10 ). This work confirms conclusions offered by Kojima and colleagues and builds on them. GAS is a clinically aggressive neoplasm with a distinctive histologic appearance. Mucinous MDA (adenoma malignum) is a morphologically welldifferentiated variant of this tumor type. Despite a high degree of histologic differentiation, it is as clinically aggressive as less differentiated varieties. There was no significant difference in age, stage, disease distribution, or outcomes between those tumors classically defined as MDA versus less well-differentiated GAS.
Although we show that GAS typically present at a higher stage than HPV-associated adenocarcinomas of the usual endocervical type, survival analysis restricted to FIGO stage I tumors indicates that the GAS remain more aggressive. Unlike HPV-associated UEA, which typically remain localized to the pelvis (while sparing ovaries) and regional lymph nodes until late in the disease course, GAS frequently metastasize to ovaries, the abdomen, the omentum (Fig. 6) , and distant sites. Rare affected patients have a familial cancer predisposition syndrome.
It is important for pathologists to be able to recognize this type of ECA because of its distinguishing clinical features. With large-scale HPV vaccination pro-grams and the projected decrease in the prevalence of HPV-associated adenocarcinomas, there is potential increase in the proportion of GAS, making early and accurate recognition even more important. Unlike HPVassociated ECAs of usual type, GAS, including minimal deviation type, are frequently centered in the upper endocervix, 36 present with a bulky cervix, 37 are usually p16negative or focal, demonstrate gastric differentiation, and may contain LEGH, its putative precursor. 9, 16, 22, 25, [38] [39] [40] We presented a more extensive description of the morphologic spectrum of these tumors in abstract form recently (manuscript in preparation) 41 ; we hope this helps pathologists better recognize these distinct tumors (Fig. 7) .
Similar to the data presented by Kojima's group, we report significantly worse survival outcomes for GAS compared with UEA. GAS, including those traditionally classified as MDA, are a distinct subset of tumors unassociated with high-risk HPV infection which have a much more aggressive phenotype and display unusual metastatic patterns compared with UEA. Patients tend to present at higher stage and, even when matched for stage I, have worse disease-specific survival. Metastatic sites include omentum, liver, brain, and bone; these are uncommonly involved organs in ECA. It is extremely im- Often at high stage Uncommonly high stage portant for pathologists to be able to recognize this rare tumor because of its aggressive nature and the diagnostic difficulties it can pose. Dependence on p16 reactivity to distinguish cervical adenocarcinoma from a benign process is a major pitfall in this tumor subtype. This also challenges the appropriateness of moving toward HPVonly testing as a screening tool for cervical cancer since these tumors will surely be missed by such testing alone.
